Tay-Sachs Disease — Research Summary
Printed from RareWays (rareways.com.au) on 11 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Long-term follow-up of a Tay-Sachs disease patient with cherry-red spot.
Tsutsumi Noriko et al. — American journal of ophthalmology case reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41783478/
- 2.
Generation and characterization of induced pluripotent stem cell (iPSC) lines from patients affected with Tay-Sachs and Sandhoff disease.
Jovanovic Vukasin M et al. — Stem cell research (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41795546/
- 3.
Tay-Sachs disease models: From cellular and animal models to treatment perspectives.
Suarez Diego A et al. — Molecular genetics and metabolism (18 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41880697/
- 4.
Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model.
Basırlı Hande et al. — Neurochemistry international (10 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41819452/
- 5.
B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease.
Yanbul Selman et al. — Neuromolecular medicine (9 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41803330/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Recruiting — Phase 3 — Azafaros A.G.
https://clinicaltrials.gov/study/NCT07054515
- 2.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
Recruiting — Phase 3 — Azafaros A.G.
https://clinicaltrials.gov/study/NCT07082543
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Tay-Sachs Disease
Tay-Sachs Disease is a rare inherited lysosomal storage disorder caused by mutations in the HEXA gene, resulting in the toxic accumulation of gangliosides in nerve cells. The infantile form is typically fatal by age 5; late-onset forms present in adolescence or adulthood. Carrier screening in at-risk populations (Ashkenazi Jewish, French-Canadian) has dramatically reduced incidence.
Most Recent Research
PURPOSE: To describe the clinical progression and ophthalmic findings in a Japanese boy with Tay-Sachs disease at ages 5 and 8 months. RESULTS: The patient was born at 38 weeks of gestation and developed normally until motor skill delays were identified at age 1 year and 1 month. At that time, brain magnetic resonance imaging revealed diffuse T2 hyperintensity in the bilateral basal ganglia. At age 1 year and 6 months, he was able to fix and follow objects, and the optic discs appeared normal, but bilateral cherry-red spots were observed in the maculae. Based on these findings, together with hypersensitivity to sound and markedly reduced β-hexosaminidase A activity, Tay-Sachs disease was biochemically diagnosed. By age 2 years and 1 month, the patient had lost the ability to fixate on and follow objects. Fundoscopy at age 4 years and 4 months revealed optic atrophy and reduced cherry-red spots, electroretinography (ERG) at age 4 years and 9 months showed a complete loss of retinal responses, and optical coherence tomography at age 5 years and 3 months demonstrated retinal thinning. Long-term observation revealed progressive degeneration, consistent with previous reports. Lipid deposition in all retinal layers was considered to contribute to retinal atrophy. CONCLUSIONS: This report highlights progressive retinal degeneration with optic atrophy, retinal thinning, and reduction in cherry-red spots. The flat ERG waveform in this patient suggests more advanced retinal involvement than in previous reports and provides insights into the ocular manifestations of Tay-Sachs disease.
Common Questions
What is Tay-Sachs Disease?
Tay-Sachs Disease is a rare inherited lysosomal storage disorder caused by mutations in the HEXA gene, resulting in the toxic accumulation of gangliosides in nerve cells. The infantile form is typically fatal by age 5; late-onset forms present in adolescence or adulthood. Carrier screening in at-risk populations (Ashkenazi Jewish, French-Canadian) has dramatically reduced incidence.
How many clinical trials are available for Tay-Sachs Disease?
RareWays currently indexes 26 clinical trials for Tay-Sachs Disease, of which 8 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Tay-Sachs Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Tay-Sachs Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.